EUVIMEDEUVIMED entdecken
Crossref

Design, Synthesis, and Integrated In Silico–In Vitro Evaluation of Triazole‐Linked Benz/Imidazole‐2‐Thione/Selone Derivatives as Selective CDK1 Inhibitors for Breast Cancer Therapy

Alameer Ezat Abdulkareem, Ahmed Hassoon Mageed iD

Archiv der Pharmazie · 2025

DOI: 10.1002/ardp.70173 ↗

Kurz gefasst

Fachartikel in der Zeitschrift Archiv der Pharmazie, 2025. Verfasst von Alameer Ezat Abdulkareem und 1 weiteren Autor:innen. Beteiligte Einrichtung: Faculty of Pharmacy, Jabir Ibn Hayyan University for Medical and Pharmaceutical Sciences, Najaf, Iraq. Hauptthemen laut MEDLINE: Drug Design, Antineoplastic Agents, Breast Neoplasms, Triazoles. Die Arbeit wurde bisher 5-mal zitiert (Crossref) und nennt 50 Literaturangaben.

AbstractSchlagwörterBibliografische AngabenZitierenVerwandte Studien

Abstract (Originalsprache)

Benz/imidazole‐2‐thione/selone‐based triazoles, particularly their thione and selone analogs, are gaining attention for anticancer drug development due to their structural diversity and biological activity. However, their potential as targeted inhibitors of cancer‐related proteins remains underexplored. This study reports the design, synthesis, and evaluation of novel benz/imidazole‐2‐thione/selone‐based triazoles, focusing on cyclin‐dependent kinase 1 (CDK1), a key regulator of cancer cell proliferation. The compounds were synthesized via a multistep approach involving imidazolium salt intermediates, followed by sulfur or selenium incorporation. Structural confirmation was achieved using FT‐IR, NMR, and mass spectrometry. Molecular docking against CDK1, TERT, and VEGFR2 revealed strong binding affinities (−9.7 to −7.3 kcal/mol), with CDK1 selected for further in vitro study using MCF‐7 breast cancer cells. Molecular dynamics (MD) simulations confirmed stable CDK1 binding for Compounds 2 , 4 , and 9 , although Compound 9 showed conformational instability after 60 ns. ADMET profiling indicated favorable drug‐likeness and permeability but highlighted metabolic liabilities and hERG inhibition risks, particularly for Compounds 4 and 9 . The target prediction and pathway enrichment analyses predict that benz/imidazole‐2‐thione/selone‐based triazoles exert their pharmacological effects primarily through the regulation of GPCR signaling pathways, likely via direct interaction with key regulators such as RGS8 and RGS4. In vitro assays demonstrated dose‐dependent cytotoxicity, with Compound 4 showing the highest potency (IC 50 = 106.12 ± 1.03 µg/mL), followed by 9 and 2 . These findings suggest that benz/imidazole‐2‐thione/selone‐based triazoles are promising CDK1 inhibitors and support their further optimization as targeted breast cancer therapies.

Schlagwörter

MeSH-Schlagwörter (MEDLINE)

Drug DesignAntineoplastic AgentsBreast NeoplasmsTriazolesProtein Kinase InhibitorsCDC2 Protein KinaseThionesHumansStructure-Activity RelationshipCell ProliferationMolecular Docking SimulationFemaleMolecular StructureMCF-7 CellsDrug Screening Assays, AntitumorDose-Response Relationship, DrugMolecular Dynamics SimulationImidazoles

Stichwörter der Autor:innen

benz/imidazole‐based triazolebreast cancermolecular dockingmolecular dynamics simulationsthione/selone‐triazole

Substanzen

Antineoplastic AgentsTriazolesProtein Kinase InhibitorsCDC2 Protein KinaseCDK1 protein, humanThionesImidazoles

Autor:innen und Institutionen

  • Faculty of Pharmacy, Jabir Ibn Hayyan University for Medical and Pharmaceutical Sciences, Najaf, Iraq.
  • Department of Chemistry, Faculty of Science, The University of Kufa, Najaf, Iraq.

ORCID-Profile: Ahmed Hassoon Mageed

Zitieren

APA

Abdulkareem, A. E., & Mageed, A. H. (2025). Design, Synthesis, and Integrated In Silico–In Vitro Evaluation of Triazole‐Linked Benz/Imidazole‐2‐Thione/Selone Derivatives as Selective CDK1 Inhibitors for Breast Cancer Therapy. Archiv der Pharmazie. https://doi.org/10.1002/ardp.70173

Vancouver

Abdulkareem AE, Mageed AH. Design, Synthesis, and Integrated In Silico–In Vitro Evaluation of Triazole‐Linked Benz/Imidazole‐2‐Thione/Selone Derivatives as Selective CDK1 Inhibitors for Breast Cancer Therapy. Archiv der Pharmazie. 2025. doi:10.1002/ardp.70173

BibTeX
@article{Abdulkareem2025,
  author = {Abdulkareem, Alameer Ezat and Mageed, Ahmed Hassoon},
  title = {Design, Synthesis, and Integrated In Silico–In Vitro Evaluation of Triazole‐Linked Benz/Imidazole‐2‐Thione/Selone Derivatives as Selective CDK1 Inhibitors for Breast Cancer Therapy},
  journal = {Archiv der Pharmazie},
  year = {2025},
  doi = {10.1002/ardp.70173}
}
Kostenlos starten →